Improved prognosis of hepatitis C‐related hepatocellular carcinoma in the era of direct‐acting antivirals
Abstract The prognostic impact of direct‐acting antivirals (DAAs) on patients with hepatitis C‐related hepatocellular carcinoma (C‐HCC) is still unclear. This study aimed to evaluate the prognosis of C‐HCC in the DAA era. We enrolled 1237 consecutive patients with treatment‐naive C‐HCC who underwent...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Health/LWW
2022-09-01
|
| Series: | Hepatology Communications |
| Online Access: | https://doi.org/10.1002/hep4.2010 |
| _version_ | 1797761701277335552 |
|---|---|
| author | Tsuyoshi Fukumoto Tatsuya Minami Makoto Moriyama Tomoharu Yamada Taijiro Wake Mizuki Nishibatake Kinoshita Naoto Fujiwara Ryo Nakagomi Takuma Nakatsuka Masaya Sato Kenichiro Enooku Hayato Nakagawa Mitsuhiro Fujishiro Shuichiro Shiina Kazuhiko Koike Ryosuke Tateishi |
| author_facet | Tsuyoshi Fukumoto Tatsuya Minami Makoto Moriyama Tomoharu Yamada Taijiro Wake Mizuki Nishibatake Kinoshita Naoto Fujiwara Ryo Nakagomi Takuma Nakatsuka Masaya Sato Kenichiro Enooku Hayato Nakagawa Mitsuhiro Fujishiro Shuichiro Shiina Kazuhiko Koike Ryosuke Tateishi |
| author_sort | Tsuyoshi Fukumoto |
| collection | DOAJ |
| description | Abstract The prognostic impact of direct‐acting antivirals (DAAs) on patients with hepatitis C‐related hepatocellular carcinoma (C‐HCC) is still unclear. This study aimed to evaluate the prognosis of C‐HCC in the DAA era. We enrolled 1237 consecutive patients with treatment‐naive C‐HCC who underwent radical radiofrequency ablation between 1999 and 2019. We also enrolled 350 patients with nonviral HCC as controls. We divided these patients into three groups according to the year of initial treatment: 1999–2005 (cohort 1), 2006–2013 (cohort 2), and 2014–2019 (cohort 3). The use of antiviral agents and their effect in patients with C‐HCC was investigated. Overall survival was evaluated for each cohort using the Kaplan‐Meier method and a multivariable Cox proportional hazards regression model. Sustained virologic response (SVR) was achieved in 52 (10%), 157 (26%), and 102 (74%) patients with C‐HCC in cohorts 1–3, respectively. The 3‐ and 5‐year survival rates of patients with C‐HCC were 82% and 59% in cohort 1; 80% and 64% in cohort 2; and 86% and 78% in cohort 3, respectively (p = 0.003). Multivariable analysis adjusted for age, liver function, and tumor extension showed that the prognosis of C‐HCC improved in cohort 3 compared to cohort 1 (adjusted hazard ratio [aHR], 0.49; 95% confidence interval [CI], 0.32–0.73; p < 0.001), whereas the prognosis of nonviral HCC did not improve significantly (aHR, 0.96; 95% CI, 0.59–1.57; p = 0.88). The prognosis of C‐HCC drastically improved with the advent of DAAs. |
| first_indexed | 2024-03-12T19:17:49Z |
| format | Article |
| id | doaj.art-461437311a9e4043ab401424ae3b9137 |
| institution | Directory Open Access Journal |
| issn | 2471-254X |
| language | English |
| last_indexed | 2024-03-12T19:17:49Z |
| publishDate | 2022-09-01 |
| publisher | Wolters Kluwer Health/LWW |
| record_format | Article |
| series | Hepatology Communications |
| spelling | doaj.art-461437311a9e4043ab401424ae3b91372023-08-02T05:25:22ZengWolters Kluwer Health/LWWHepatology Communications2471-254X2022-09-01692496251210.1002/hep4.2010Improved prognosis of hepatitis C‐related hepatocellular carcinoma in the era of direct‐acting antiviralsTsuyoshi Fukumoto0Tatsuya Minami1Makoto Moriyama2Tomoharu Yamada3Taijiro Wake4Mizuki Nishibatake Kinoshita5Naoto Fujiwara6Ryo Nakagomi7Takuma Nakatsuka8Masaya Sato9Kenichiro Enooku10Hayato Nakagawa11Mitsuhiro Fujishiro12Shuichiro Shiina13Kazuhiko Koike14Ryosuke Tateishi15Department of Gastroenterology Graduate School of Medicine The University of Tokyo Tokyo JapanDepartment of Gastroenterology Graduate School of Medicine The University of Tokyo Tokyo JapanDepartment of Gastroenterology Graduate School of Medicine The University of Tokyo Tokyo JapanDepartment of Gastroenterology Graduate School of Medicine The University of Tokyo Tokyo JapanDepartment of Gastroenterology Graduate School of Medicine The University of Tokyo Tokyo JapanDepartment of Gastroenterology Graduate School of Medicine The University of Tokyo Tokyo JapanDepartment of Gastroenterology Graduate School of Medicine The University of Tokyo Tokyo JapanDepartment of Gastroenterology Graduate School of Medicine The University of Tokyo Tokyo JapanDepartment of Gastroenterology Graduate School of Medicine The University of Tokyo Tokyo JapanDepartment of Gastroenterology Graduate School of Medicine The University of Tokyo Tokyo JapanDepartment of Gastroenterology Graduate School of Medicine The University of Tokyo Tokyo JapanDepartment of Gastroenterology Graduate School of Medicine The University of Tokyo Tokyo JapanDepartment of Gastroenterology Graduate School of Medicine The University of Tokyo Tokyo JapanDepartment of Gastroenterology Juntendo University Tokyo JapanDepartment of Gastroenterology Graduate School of Medicine The University of Tokyo Tokyo JapanDepartment of Gastroenterology Graduate School of Medicine The University of Tokyo Tokyo JapanAbstract The prognostic impact of direct‐acting antivirals (DAAs) on patients with hepatitis C‐related hepatocellular carcinoma (C‐HCC) is still unclear. This study aimed to evaluate the prognosis of C‐HCC in the DAA era. We enrolled 1237 consecutive patients with treatment‐naive C‐HCC who underwent radical radiofrequency ablation between 1999 and 2019. We also enrolled 350 patients with nonviral HCC as controls. We divided these patients into three groups according to the year of initial treatment: 1999–2005 (cohort 1), 2006–2013 (cohort 2), and 2014–2019 (cohort 3). The use of antiviral agents and their effect in patients with C‐HCC was investigated. Overall survival was evaluated for each cohort using the Kaplan‐Meier method and a multivariable Cox proportional hazards regression model. Sustained virologic response (SVR) was achieved in 52 (10%), 157 (26%), and 102 (74%) patients with C‐HCC in cohorts 1–3, respectively. The 3‐ and 5‐year survival rates of patients with C‐HCC were 82% and 59% in cohort 1; 80% and 64% in cohort 2; and 86% and 78% in cohort 3, respectively (p = 0.003). Multivariable analysis adjusted for age, liver function, and tumor extension showed that the prognosis of C‐HCC improved in cohort 3 compared to cohort 1 (adjusted hazard ratio [aHR], 0.49; 95% confidence interval [CI], 0.32–0.73; p < 0.001), whereas the prognosis of nonviral HCC did not improve significantly (aHR, 0.96; 95% CI, 0.59–1.57; p = 0.88). The prognosis of C‐HCC drastically improved with the advent of DAAs.https://doi.org/10.1002/hep4.2010 |
| spellingShingle | Tsuyoshi Fukumoto Tatsuya Minami Makoto Moriyama Tomoharu Yamada Taijiro Wake Mizuki Nishibatake Kinoshita Naoto Fujiwara Ryo Nakagomi Takuma Nakatsuka Masaya Sato Kenichiro Enooku Hayato Nakagawa Mitsuhiro Fujishiro Shuichiro Shiina Kazuhiko Koike Ryosuke Tateishi Improved prognosis of hepatitis C‐related hepatocellular carcinoma in the era of direct‐acting antivirals Hepatology Communications |
| title | Improved prognosis of hepatitis C‐related hepatocellular carcinoma in the era of direct‐acting antivirals |
| title_full | Improved prognosis of hepatitis C‐related hepatocellular carcinoma in the era of direct‐acting antivirals |
| title_fullStr | Improved prognosis of hepatitis C‐related hepatocellular carcinoma in the era of direct‐acting antivirals |
| title_full_unstemmed | Improved prognosis of hepatitis C‐related hepatocellular carcinoma in the era of direct‐acting antivirals |
| title_short | Improved prognosis of hepatitis C‐related hepatocellular carcinoma in the era of direct‐acting antivirals |
| title_sort | improved prognosis of hepatitis c related hepatocellular carcinoma in the era of direct acting antivirals |
| url | https://doi.org/10.1002/hep4.2010 |
| work_keys_str_mv | AT tsuyoshifukumoto improvedprognosisofhepatitiscrelatedhepatocellularcarcinomaintheeraofdirectactingantivirals AT tatsuyaminami improvedprognosisofhepatitiscrelatedhepatocellularcarcinomaintheeraofdirectactingantivirals AT makotomoriyama improvedprognosisofhepatitiscrelatedhepatocellularcarcinomaintheeraofdirectactingantivirals AT tomoharuyamada improvedprognosisofhepatitiscrelatedhepatocellularcarcinomaintheeraofdirectactingantivirals AT taijirowake improvedprognosisofhepatitiscrelatedhepatocellularcarcinomaintheeraofdirectactingantivirals AT mizukinishibatakekinoshita improvedprognosisofhepatitiscrelatedhepatocellularcarcinomaintheeraofdirectactingantivirals AT naotofujiwara improvedprognosisofhepatitiscrelatedhepatocellularcarcinomaintheeraofdirectactingantivirals AT ryonakagomi improvedprognosisofhepatitiscrelatedhepatocellularcarcinomaintheeraofdirectactingantivirals AT takumanakatsuka improvedprognosisofhepatitiscrelatedhepatocellularcarcinomaintheeraofdirectactingantivirals AT masayasato improvedprognosisofhepatitiscrelatedhepatocellularcarcinomaintheeraofdirectactingantivirals AT kenichiroenooku improvedprognosisofhepatitiscrelatedhepatocellularcarcinomaintheeraofdirectactingantivirals AT hayatonakagawa improvedprognosisofhepatitiscrelatedhepatocellularcarcinomaintheeraofdirectactingantivirals AT mitsuhirofujishiro improvedprognosisofhepatitiscrelatedhepatocellularcarcinomaintheeraofdirectactingantivirals AT shuichiroshiina improvedprognosisofhepatitiscrelatedhepatocellularcarcinomaintheeraofdirectactingantivirals AT kazuhikokoike improvedprognosisofhepatitiscrelatedhepatocellularcarcinomaintheeraofdirectactingantivirals AT ryosuketateishi improvedprognosisofhepatitiscrelatedhepatocellularcarcinomaintheeraofdirectactingantivirals |